Legend Biotech Corp (LEGN) - Total Liabilities
Based on the latest financial reports, Legend Biotech Corp (LEGN) has total liabilities worth $521.32 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Legend Biotech Corp long-term investment allocation to see how much of total assets are deployed in long-term investments.
Legend Biotech Corp - Total Liabilities Trend (2017–2025)
This chart illustrates how Legend Biotech Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see LEGN current and non-current assets.
Legend Biotech Corp Competitors by Total Liabilities
The table below lists competitors of Legend Biotech Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quebecor Inc
TO:QBR-A
|
Canada | CA$9.97 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥3.02 Billion |
|
BBVA Banco Frances SA
BA:BBAR
|
Argentina | AR$21.87 Trillion |
|
Life360, Inc. Common Stock
NASDAQ:LIF
|
USA | $438.49 Million |
|
GZ Port
SHG:601228
|
China | CN¥29.16 Billion |
|
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
|
USA | $264.41 Million |
|
Viohalco S.A
BR:VIO
|
Belgium | €-2.36 Billion |
|
Firefly Aerospace Inc. Common Stock
NASDAQ:FLY
|
USA | $416.30 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Legend Biotech Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Legend Biotech Corp balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Legend Biotech Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Legend Biotech Corp (2017–2025)
The table below shows the annual total liabilities of Legend Biotech Corp from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $731.60 Million | +16.20% |
| 2024-12-31 | $629.61 Million | +5.42% |
| 2023-12-31 | $597.24 Million | +1.80% |
| 2022-12-31 | $586.65 Million | +65.95% |
| 2021-12-31 | $353.52 Million | +189.13% |
| 2020-12-31 | $122.27 Million | -70.22% |
| 2019-12-31 | $410.58 Million | -2.33% |
| 2018-12-31 | $420.40 Million | +85.59% |
| 2017-12-31 | $226.53 Million | -- |
About Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more